SG11202008864VA - Intracellular delivery of biomolecules to modify immune response - Google Patents

Intracellular delivery of biomolecules to modify immune response

Info

Publication number
SG11202008864VA
SG11202008864VA SG11202008864VA SG11202008864VA SG11202008864VA SG 11202008864V A SG11202008864V A SG 11202008864VA SG 11202008864V A SG11202008864V A SG 11202008864VA SG 11202008864V A SG11202008864V A SG 11202008864VA SG 11202008864V A SG11202008864V A SG 11202008864VA
Authority
SG
Singapore
Prior art keywords
biomolecules
immune response
intracellular delivery
modify immune
modify
Prior art date
Application number
SG11202008864VA
Other languages
English (en)
Inventor
Scott Loughhead
Leeann Talarico
Alfonso Vicente-Suarez
Matt Booty
Howard Bernstein
Katarina Blagovic
Armon R Sharei
Kelan Hlavaty
Original Assignee
Sqz Biotechnologies Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sqz Biotechnologies Co filed Critical Sqz Biotechnologies Co
Publication of SG11202008864VA publication Critical patent/SG11202008864VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • General Engineering & Computer Science (AREA)
SG11202008864VA 2018-03-12 2019-03-11 Intracellular delivery of biomolecules to modify immune response SG11202008864VA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862641987P 2018-03-12 2018-03-12
US201862738941P 2018-09-28 2018-09-28
US201962794516P 2019-01-18 2019-01-18
PCT/US2019/021705 WO2019178006A2 (en) 2018-03-12 2019-03-11 Intracellular delivery of biomolecules to modify immune response

Publications (1)

Publication Number Publication Date
SG11202008864VA true SG11202008864VA (en) 2020-10-29

Family

ID=66102189

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008864VA SG11202008864VA (en) 2018-03-12 2019-03-11 Intracellular delivery of biomolecules to modify immune response

Country Status (16)

Country Link
EP (1) EP3765068A2 (zh)
JP (1) JP2021517813A (zh)
KR (1) KR20200130835A (zh)
CN (1) CN112135627A (zh)
AU (1) AU2019234550A1 (zh)
BR (1) BR112020018612A2 (zh)
CA (1) CA3093828A1 (zh)
CO (1) CO2020012584A2 (zh)
CR (1) CR20200460A (zh)
IL (1) IL277188A (zh)
MA (1) MA52010A (zh)
MX (1) MX2020009439A (zh)
PH (1) PH12020551436A1 (zh)
SG (1) SG11202008864VA (zh)
TW (1) TW202003019A (zh)
WO (1) WO2019178006A2 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017041051A1 (en) 2015-09-04 2017-03-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
JP6884450B2 (ja) * 2019-02-14 2021-06-09 学校法人獨協学園獨協医科大学 Ｔ細胞ワクチン
BR112021016903A2 (pt) 2019-02-28 2021-11-03 Sqz Biotechnologies Co Administração de biomoléculas a pbmcs para modificação de uma resposta imune
AU2020271040A1 (en) 2019-04-08 2021-11-18 Sqz Biotechnologies Company Cartridge for use in a system for delivery of a payload into a cell
MX2022014134A (es) 2020-05-11 2022-11-30 Hoffmann La Roche Tratamiento conjunto con pbmc modificadas y un inmunoconjugado.
JP2023535982A (ja) 2020-07-29 2023-08-22 スクイーズ バイオテクノロジーズ カンパニー 無核細胞を使用して変異型Ｒａｓに対する免疫応答を刺激する方法
EP4188428A1 (en) 2020-07-29 2023-06-07 SQZ Biotechnologies Company Methods to stimulate immune responses to mutant ras using nucleated cells
WO2022147017A1 (en) 2020-12-29 2022-07-07 Sqz Biotechnologies Company Formulations for cryopreservation of pbmcs
US20220296691A1 (en) 2020-12-29 2022-09-22 Sqz Biotechnologies Company Methods for treating cancer with activating antigen carriers
US20220233676A1 (en) 2020-12-29 2022-07-28 Sqz Biotechnologies Company Formulations of activating antigen carriers
EP4271711A1 (en) 2020-12-29 2023-11-08 SQZ Biotechnologies Company Methods for treating cancers with modified pbmcs
CN115252772A (zh) * 2021-04-30 2022-11-01 华普生物技术(江苏)股份有限公司 人工合成的含CpG单链脱氧寡核苷酸在疫苗中的应用
WO2023010090A1 (en) 2021-07-29 2023-02-02 Sqz Biotechnologies Company Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery
WO2023087009A1 (en) 2021-11-11 2023-05-19 Sqz Biotechnologies Company Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery
WO2024026491A2 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Enhanced antigen presenting cell formulations
WO2024026492A1 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Methods for treating cancer with enhanced antigen presenting cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1699479A1 (en) * 2003-12-24 2006-09-13 Leiden University Medical Center Synthetic protein as tumor-specific vaccine
AU2008269721B2 (en) * 2007-05-31 2013-01-10 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Intradermal HPV peptide vaccination
DK2429585T3 (en) * 2009-05-15 2018-07-30 Irx Therapeutics Inc VACCINE IMMUNOTHERAPY
RS59898B1 (sr) 2011-10-17 2020-03-31 Massachusetts Inst Technology Intraćelijsko davanje
SG10201903912XA (en) * 2014-10-31 2019-05-30 Massachusetts Inst Technology Delivery of biomolecules to immune cells
EP3344747B1 (en) 2015-09-04 2022-11-09 SQZ Biotechnologies Company Intracellular delivery of biomolecules mediated by a surface with pores
WO2017123663A1 (en) * 2016-01-12 2017-07-20 Sqz Biotechnologies Company Intracellular delivery of complexes

Also Published As

Publication number Publication date
PH12020551436A1 (en) 2021-09-06
CO2020012584A2 (es) 2020-11-20
JP2021517813A (ja) 2021-07-29
WO2019178006A2 (en) 2019-09-19
RU2020132504A (ru) 2022-04-13
AU2019234550A1 (en) 2020-10-01
IL277188A (en) 2020-10-29
CA3093828A1 (en) 2019-09-19
CR20200460A (es) 2020-11-23
KR20200130835A (ko) 2020-11-20
BR112020018612A2 (pt) 2020-12-29
TW202003019A (zh) 2020-01-16
WO2019178006A3 (en) 2019-11-07
MA52010A (fr) 2021-01-20
EP3765068A2 (en) 2021-01-20
RU2020132504A3 (zh) 2022-04-13
MX2020009439A (es) 2021-01-08
CN112135627A (zh) 2020-12-25

Similar Documents

Publication Publication Date Title
IL277188A (en) Intracellular delivery of biomolecules to modify the immune response
IL262677A (en) Intracellular delivery of biomolecules to induce tolerance
IL262676B1 (en) Intracellular delivery of biomolecules to induce tolerance
IL285809A (en) Administration of biomolecules to pbmcs to modulate immune response
IL261188A (en) Antibodies against tigit
IL252005A0 (en) Transfer of biological molecules to immune cells
IL269499A (en) Stable antibody formulation
IL268881A (en) Use of anti-CTLA-4 antibodies with increased ADCC, to increase the immune response to vaccine-A
PL3344747T3 (pl) Wewnątrzkomórkowe dostarczanie biocząsteczek za pośrednictwem powierzchni z porami
IL268731A (en) New uses of anti-SIRPG antibodies
HK1257455A1 (zh) TGFβ2抗體
IL275549B (en) Mapping of entities to accounts
HK1256033A1 (zh) 用於刺激免疫系統的肽
DK3380120T3 (da) Immunstimulerende sammensætninger
DK3191515T3 (da) Ligander der forstærker gonadotropiners bioaktivitet
IL275079A (en) DARIC interleukin receptors
GB201609742D0 (en) Improvements relating to antibodies
LU92637B1 (en) Capsule to contain powder preparation therein
IL274231A (en) Modulators of ENAC expression
IL272933A (en) Preparation of solid tablets containing antibodies by solution/suspension layering
IL269169A (en) New dosage form
IL272015A (en) Antibodies to MADCAM
HUE059558T2 (hu) Stabilizált béta-interferon variáns készítmény
SG10201700022QA (en) Intradermal Administration Of Immunoglobulin G Preparation
ZA202100026B (en) Complex for enhancing immune response